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Abstract
Aims
Mutations in the cardiac myosin-binding protein C gene (MYBPC3) are the most common
genetic cause of hypertrophic cardiomyopathy (HCM) worldwide. The molecular mecha-
nisms leading to HCM are poorly understood. We investigated the metabolic profiles of
mutation carriers with the HCM-causingMYBPC3-Q1061X mutation with and without left
ventricular hypertrophy (LVH) and non-affected relatives, and the association of the meta-
bolome to the echocardiographic parameters.
Methods and Results
34 hypertrophic subjects carrying theMYBPC3-Q1061X mutation, 19 non-hypertrophic
mutation carriers and 20 relatives with neither mutation nor hypertrophy were examined
using comprehensive echocardiography. Plasma was analyzed for molecular lipids and
polar metabolites using two metabolomics platforms. Concentrations of branched chain
amino acids, triglycerides and ether phospholipids were increased in mutation carriers with
hypertrophy as compared to controls and non-hypertrophic mutation carriers, and corre-
lated with echocardiographic LVH and signs of diastolic and systolic dysfunction in subjects
with theMYBPC3-Q1061X mutation.
Conclusions
Our study implicates the potential role of branched chain amino acids, triglycerides and
ether phospholipids in HCM, as well as suggests an association of these metabolites with
remodeling and dysfunction of the left ventricle.
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Introduction
Hypertrophic cardiomyopathy (HCM) is an autosomally inherited myocardial disease occur-
ring in approximately 1 out of 500 individuals [1]. Mutations in the genes encoding mainly car-
diac sarcomeric proteins result in ventricular hypertrophy and dysfunctional myocardium.
HCM patients have an increased risk of sudden death, and HCM is the most common cause of
sudden cardiac death attributable to fatal ventricular arrhythmias in athletes and adolescents.
Although many patients remain asymptomatic through life, some develop dyspnea, arrhyth-
mias and end-stage heart failure [1].
Mutations of the myosin-binding protein C (MYBPC) gene often result in truncated pro-
teins, and are the most common genetic cause of HCM worldwide [2]. In Finland, a novel
founder mutation of the cardiac myosin-binding protein C gene (MYBPC3-Q1061X) has been
identified in Finnish HCM patients, which leads to a truncated protein lacking the binding
sites for myosin and titin [3,4] (S1 Fig). This mutation accounts for approximately 11% of
HCM in Finnish patients, and is the most prevalent HCM-causing mutation in Finland with a
penetrance of approximately 78% [5]. BecauseMYBPC3mutations in previous studies have
been reported to have a rather favorable prognosis, it may be even more common [6,7]. Gener-
ally, the phenotype of subjects withMYBPC3mutations is variable, and cardiac hypertrophy
usually does not manifest until early adolescence with penetrance increasing with age and
peaking at approximately 60 years of age [8–10]. The molecular mechanisms leading to HCM
in mutation carriers, such as asymmetric hypertrophy, myofibrillar disarray and fibrosis, are
poorly understood.
Metabolomics is the global study of metabolites, such as lipids, sugars and amino acids, in
cells, tissues and biofluids. The metabolome is sensitive to various pathogenically relevant fac-
tors including genetic variation, diet, age, immune system status and gut microbiota [11–15].
Metabolomics is therefore a powerful tool for the characterization of complex phenotypes
affected by genetic and environmental factors as well as the interactions thereof [16]. Metabo-
lomics studies in HCM and other cardiovascular diseases are of particular interest, both to bet-
ter understand the pathophysiology and to identify novel biomarkers [17]. Since
cardiovascular diseases are often characterized by long prodromal periods, with clinical symp-
toms occurring rather late in the pathogenesis, it is important to identify individuals at high
risk in the prodromal phase when intervention would be most optimal. Several different
metabolite profiling methods have been developed, which allow for extensive and quantitative
investigation of a large amount of different metabolites [18]. To our knowledge, no metabolo-
mics studies on HCM in humans have so far been reported.
We aimed to investigate the metabolic profiles of carriers of theMYBPC3-Q1061X mutation
with and without left ventricular hypertrophy (LVH), and compare these profiles to those of
subjects with neither the mutation nor LVH. All subjects were assessed with comprehensive
echocardiography including tissue Doppler imaging. Plasma samples were analyzed with two
analytical platforms for metabolomics, with broad analytical coverage of molecular lipids and
polar metabolites.
Methods
Subjects
A total of 73 genotyped subjects from families carrying theMYBPC3-Q1061X mutation were
recruited from the Helsinki and Kuopio University Hospital regions. Mutation carriers diag-
nosed with clinical HCM (maximum wall thickness of left ventricle (MWT) 13 mm on echo-
cardiography) numbering 34 patients were included in the G+/LVH+ group. The G+/LVH-
Metabolome in FinnishMYBPC3-Q1061X Mutation Carriers
PLOS ONE | DOI:10.1371/journal.pone.0134184 August 12, 2015 2 / 15
aka.fi/en-GB/A/; The Finnish Medical Foundation to T.
Heliö, URL: http://www.european-funding-guide.eu/
scholarship/14778-scholarship; The special
governmental subsidy for health sciences research of
the University Hospital of Helsinki (TYH2012120;
TYH2014208) to T. Heliö, URL: http://www.hyksin.
com/en/index.php/Company/Helsinki%20University%
20Hospital; The Aarne Koskelo Foundation to M.J.,
URL: http://www.aarnekoskelonsaatio.fi/; and The
Research Council of Norway (214191) to B.J., URL:
http://www.forskningsradet.no/en/Home_page/
1177315753906. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
group included 19 mutation carriers without hypertrophy (MWT< 13 mm), and the control
group included 20 subjects from the same families with neither the mutation nor LVH. Exclu-
sion criteria were age (<18 years) and pregnancy. The cardiac phenotype of the subjects was
characterized by anthropometrics, blood samples and echocardiography. The blood samples
were collected in the fasting state (12 hours) and immediately centrifuged at 3200 G for 10
minutes at 4°C. Plasma was separated and stored at -70°C (Kuopio) and -80°C (Helsinki). The
local ethics committees of the University Hospitals of Helsinki and Kuopio in Finland
approved the study protocol (96/2008). The study is in agreement with the principles outlined
in the Declaration of Helsinki. All patients gave written consent.
Echocardiography
To assess cardiac structural changes and cardiac function, GE Vivid 7 ultrasound equipment
with an M4S probe at the University Hospitals of Helsinki and Kuopio were used. Echocardi-
ography was performed by experienced clinical cardiologists (MJ, PJ, JK). Measurements were
analyzed offline with EchoPac software (GE Vingmed, version 10.0.1, Norway) by the same
observer (MJ) blinded to clinical and genetic data at the Helsinki University Central Hospital.
Conventional measurements of cardiac anatomy and function were performed with M-
mode, 2D and pulsed-wave Doppler according to guidelines [19]. Biplane Simpson method in
the apical four- and two-chamber views was used to measure left ventricular ejection fraction
(LVEF). Parasternal short axis views were used to measure maximum wall thickness (MWT).
If apical hypertrophy was suggested by imaging an apical view was employed. Presence of sys-
tolic anterior motion (SAM) and left ventricular outflow tract (LVOT) obstruction, defined as
a gradient of 30 mmHg measured at rest, were recorded. Left ventricular mass (LV mass)
was calculated by the formula: 0.80 (1.04 x [PWT + SWT+LVEDD]3 –LVEDD3) + 0.6), where
PWT and SWT is posterior and septal wall thickness, respectively, and LVEDD is left ventricu-
lar internal diameter at diastole [20].
Tissue Doppler imaging (TDI) velocities of systolic (Sm) and early diastolic motion (Em)
were measured from the septal and lateral mitral valve annulus.
Metabolomic analysis
Two analytical platforms for metabolic profiling were applied to all samples: (a) platform for
global profiling of small, polar metabolites, based on comprehensive two-dimensional gas
chromatography coupled with time-of-flight mass spectrometry (GC×GC-TOFMS), covering
molecules such as sugars, sterols, amino acids and various organic acids, including free fatty
acids and ketoacids; (b) global lipidomics platform based on ultra performance liquid chroma-
tography coupled to quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS), covering
various molecular lipids such as phospholipids, triglycerides, sphingolipids and neutral lipids.
Both platforms have been extensively described [21,22], and are also described in the S1 Meth-
ods. The raw data from UPLC-QTOFMS platform were processed with MZmine 2 [23], while
the GC×GC-TOFMS data were processed with the Guineu software [21].
A total of 699 molecular lipids and 1603 small polar metabolites were detected, of which
238 lipids and 215 metabolites were identified. Only lipids and metabolites identified and
found in at least 70% of the samples were used in the statistical analysis.
Cluster analysis
The lipidomics and metabolomics data were scaled with zero mean and unit variance to make
the profiles comparable with each other, and Bayesian model-based clustering was applied on
the scaled data to group metabolites with similar profiles across all samples. The clustering was
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performed using the mclust [24] method, implemented in R [25] in the package “metadar”
[26]. In mclust, the observed data are viewed as a mixture of several clusters and each cluster
comes from a unique probability density function. A number of clusters in the mixture,
together with the cluster-specific parameters that constrain the probability distributions, will
define a model, which can then be compared with others. The clustering process selects the
optimal model and determines the data partition accordingly.
Statistical analyses and linear mixed models
Statistical analyses were performed with R version 2.15.0 for Windows (R Development Core
Team (2011), R Foundation for Statistical Computing, Vienna, Austria) and IBM SPSS Ver-
sion 19.0 (IBM Corp. Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk,
NY: IBM Corp.). Most analyses and visualization in R were performed using the “metadar”
package for metabolomics data analysis [26]. Clinical, echocardiographic and individual
metabolite level data between the study groups were compared with the independent samples
T-test or Fisher’s exact test for 2 groups and for 3-groups we employed one-way analysis of
variance (ANOVA) with pairwise comparison adjusted with the Bonferroni correction or
Tukey’s range test. The average within-cluster metabolite profiles between the three groups
were analyzed with one-way ANOVA. Analysis of covariance (ANVOCA) was performed by
adjusting the data for age and gender, and then performing one-way ANOVA on the adjusted
data. Individual metabolite levels were visualized using beanplots [27], implemented in the
‘beanplot’ R package. Beanplots provide information on the mean metabolite level within
each group, the density of the data-point distribution, as well as show individual data points.
To assess the association between metabolic profile and echocardiographic parameters in
mutation carriers with and without hypertrophy, correlation analyses using Spearman prod-
uct-moment correlation for pairwise complete data were performed in R, as implemented in
“metadar” [26]. Scatterplots and linear regression between metabolite levels and echocardio-
graphic parameters were performed in SPSS. All tests were assessed with a significance level of
p 0.05.
Results
Clinical characteristics and echocardiography
The baseline clinical characteristics are presented in Table 1. There were more male subjects in
the pooled G+ mutation carrier group compared to the control group. The subjects in the G
+ group were only asymptomatic or mildly symptomatic (New York Heart Association Func-
tional Classification class I-II). Some of the subjects in both study groups had hypertension,
and a few of the subjects in the G+ group had atrial fibrillation (AF). There was no difference
in the body mass index, heart rate, blood pressure or lipid levels between the control and G
+ groups. There was no significant difference in age between the control and G+ subjects, but
in the subgroups analysis, G+/LVH- subjects were younger than subjects in other two groups
(data not shown). Baseline data is listed in S1 Dataset.
Echocardiographic data in control, G+/LVH- and G+/LVH+ groups are shown in Table 2.
Left ventricular dimensions and ejection fraction (LVEF) were within normal range in all three
groups. By definition, MWT and LV mass were higher in hypertrophic subjects compared to
non-hypertrophic subjects. Left atrial size was larger in the G+/LVH+ group compared to
other two groups. There was no difference in LVOT gradient between the three groups, but 7
patients of the G+/LVH+ groups had systolic anterior motion of the mitral valve apparatus
(SAM) and two had LVOT obstruction (LVOT gradient> 30 mmHg at rest). Mitral valve E
velocity did not differ between the study groups. TDI septal and lateral annular Sm was
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diminished in the G+/LVH+ group indicating systolic dysfunction despite preserved LVEF. In
the G+/LVH+ group, early diastolic velocities at the lateral and septal mitral annulus were sig-
nificantly lower compared to other two groups, consistent with diastolic dysfunction typical of
HCM. The G+/LVH- group had higher TDI lateral Em compared to the control group, pre-
sumably because the G+/LVH- group was younger than the control group. Otherwise there
were no significant differences in baseline echocardiographic variables between the G+/LVH-
and control groups (Table 2). Echocardiographic data is listed in S2 Dataset.
Association of the global metabolome with the MYBPC3-Q1061X
mutation and LVH
Following the data processing and filtering as described in Methods, a total of 86 polar metabo-
lites and 238 molecular lipids were included in the data analysis. Metabolite-data are listed in
S3 Dataset, as is lipid-data (S4 Dataset). Since many metabolites are co-regulated, it cannot be
assumed that the profiles of all measured metabolites are independent [28]. Therefore, all lipids
and metabolites were first surveyed by clustering of the data into subsets using Bayesian
model-based clustering [24]. The identified lipids and polar metabolites were decomposed into
seven and four clusters, respectively (LC1-LC7, MC1-MC4; Table 3). The division of lipid clus-
ters reflects different lipid functional and structural groups, while the metabolite profiles are
decomposed into three small clusters and one large cluster comprising different metabolite
functional groups. When comparing the three groups (one-way ANOVA), one of the lipid
clusters reached significance level (LC3) while one lipid (LC5) and one metabolite (MC4) clus-
ter were marginally significant (Fig 1a).
The lipid cluster LC3 which mainly includes long-chain polyunsaturated fatty acid (PUFA)
containing triglycerides (TGs), and phospholipids (plasmalogens) was significantly elevated in
HCM patients (p = 0.037), especially when compared to the control group (p = 0.047, Tukey’s
Table 1. Clinical characteristics of theMYBPC3-Q1061Xmutation carriers (G+) and control group.
Baseline Control (N = 20) G+ (N = 53) p-value
Male 5/25% 29/55% 0.035
Age (years) 46 ± 17 46 ± 15 0.906
Body mass index 25 ± 4 26 ± 5 0.356
Hypertension 5/25% 15/28% 1.000
Diabetes 2/10% 4/8% 0.663
Atrial ﬁbrillation (N/%) 0/0% 4/8% 0.57
NYHA
I 49/92%
II 4/8%
Heart rate (bpm) 63 ± 8 62 ± 10 0.878
Systolic blood pressure (mmHg) 133 ± 13 127 ± 16 0.167
Diastolic blood pressure (mmHg) 78 ± 9 77 ± 9 0.690
Cholesterol (mmol/l) 4.4 ± 0.9 4.5 ± 0.8 0.606
LDL (mmol/l) 2.6 ± 0.7 2.6 ± 0.8 0.970
HDL (mmol/l) 1.4 ± 0.3 1.4 ± 0.5 0.789
Triglycerides (mmol/l) 0.9 ± 0.6 1.2 ± 0.7 0.095
Values are presented as mean ± SD or count and percentage, with p-values for T-test or Fisher’s exact test
between groups. NYHA = New York Heart Association functional class, LDL = low-density lipoprotein,
HDL = high-density lipoprotein.
doi:10.1371/journal.pone.0134184.t001
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range test). This indicates that increased levels of TGs and phospholipids with a high degree of
double bonds are associated with HCM caused byMYBPC3-Q1061X. The remaining lipid clus-
ters also tended to be higher in HCM patients, although none of these differences were statisti-
cally significant.
Table 2. Echocardiographic parameters for the study subjects.
Echocardiography Control (N = 20) G+/LVH- (N = 19) G+/LVH+ (N = 34) p-value
LVEDD (mm) 49 ± 5 46 ± 6 46 ± 8 0.352
LVESD (mm) 28 ± 4 30 ± 6 30 ± 9 0.838
LVEF (%) 61 ± 5 61 ± 5 61 ± 11 0.997
MWT (mm) 10.3 ± 1.0 10.6 ± 1.4 20.4 ± 5.9 a,b < 0.001
LV Mass (g) 154 ± 35 148 ± 55 258 ± 100 a,b < 0.001
LAD (mm) 33 ± 5 34 ± 5 39 ± 8 a,b < 0.001
LVOT gradient (mmHg) 7.1 ± 2.9 5.7 ± 1.8 8.9 ± 12.0 0.398
MV E velocity (m/s) 0.8 ± 0.1 0.8 ± 0.2 0.7 ± 0.2 0.100
TDI Lateral Sm (cm/s) 9.0 ± 3.1 9.9 ± 2.5 6.5 ± 1.9 a,b < 0.001
TDI Septal Sm (cm/s) 8.1 ± 2.0 7.9 ± 1.4 6.6 ± 1.7 a,b 0.002
TDI Lateral Em (cm/s) 12.2 ± 4.6 15.8 ± 4.1c 9.1 ± 3.9 a,b < 0.001
TDI Septal Em (cm/s) 11.3 ± 3.8 11.9 ± 2.6 6.4 ± 2.8 a,b < 0.001
The parameters are referred to as mean ± SD. Abbreviations: LVEDD left ventricular (LV) internal diameter in diastole, LVESD LV internal diameter in
systole, LVEF left ventricular ejection fraction, MWT maximum wall thickness, LV Mass left ventricular mass, LAD left atrium diameter, LVOT gradient left
ventricular outﬂow tract gradient, MV E velocity mitral valve E-wave peak velocity, TDI Lateral Sm TDI peak systolic velocity at lateral mitral annulus, TDI
Septal Sm TDI peak systolic velocity at septal mitral annulus, TDI Septal Em TDI peak early diastolic velocity at septal mitral annulus, TDI Lateral Em
peak early diastolic velocity at lateral mitral annulus. P-values are given as one-way ANOVA. Pairwise comparisons with Bonferroni corrected p-values are
labeled:
aP<0.05 between G+/LVH+ and control group,
bP<0.05 between G+/LVH+ and G+/LVH-,
cP<0.05 between G+/LVH- and control group.
doi:10.1371/journal.pone.0134184.t002
Table 3. Description of metabolite clusters from the lipidomics (LC) andmetabolomics (MC) platforms.
Cluster Cluster-
size
Description Examples of metabolites
LC1 46 Mainly PCs, but also PEs and TGs PC(36:4), PE(34:1), TG(53:2)
LC2 86 Mainly PCs with ether-linkages and PEs, but also ChoEs, SMs, TGs PC(38:5e), PE(40:3), ChoE(18:2), PC(40:4), SM
(d18:1/22:1)
LC3 36 PUFA-containing PC and PE (plasmalogens) and PUFA-containing TGs PC(38:6), PE(40:6), TG(56:7)
LC4 10 LysoPCs LysoPC(18:2)
LC5 21 Mainly saturated TGs and 1–3 double bonds, longer chains than LC6 TG(50:1), TG(50:3), TG(54:0)
LC6 19 Saturated TGs and TGs with 1–3 double bonds, shorter chains than LC3,
LC5 and LC7
TG(42:1), TG(47:0), TG(48:3)
LC7 20 PUFA-containing TGs, long chains TG(51:5), TG(54:3), TG(54:7)
MC1 69 Diverse 4-methyl-2-oxovaleric acid, valine, hexanoic acid
MC2 11 Carboxylic acids Linoleic acid, oleic acid
MC3 4 Carboxylic acids Hexadecanoic acid, phosphoric acid
MC4 2 Branched-chain amino acids Leucine and isoleucine
Abbreviations: PC phosphatidylcholine, PE phosphatidylethanolamine, TG triglyceride, ChoE cholesteryl ester, SM sphingomyelin, PUFA polyunsaturated
fatty acid, lysoPC lysophosphatidylcholine.
doi:10.1371/journal.pone.0134184.t003
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Fig 1. Metabolomic profiles across the three study groups. (a) Mean metabolite levels within each cluster for the three groups. The error bars show
standard error of the mean (SEM), and cluster LC3 is the only significant cluster. Nominal p-values are shown (one-way ANOVA). (b) Profiles of selected
representative metabolites from different clusters in all three groups. The metabolite levels are shown as beanplots [27], which provide information on the
mean level (solid line), individual data point (short black lines), and the density of the distribution.
doi:10.1371/journal.pone.0134184.g001
Metabolome in FinnishMYBPC3-Q1061X Mutation Carriers
PLOS ONE | DOI:10.1371/journal.pone.0134184 August 12, 2015 7 / 15
One of the smaller clusters comprising polar metabolites, MC4, contains two branched
chain amino acids (BCAAs) leucine and isoleucine, while two other small clusters contain car-
boxylic acids. The large cluster contains various metabolites, among others 4-methyl-2-oxova-
leric acid, a catabolic product of leucine, and several organic acids involved in the citric acid
cycle, including α-ketoglutaric acid and malic acid.
Association of molecular lipids and polar metabolites with the
MYBPC3-Q1061X mutation and LVH
When analyzing the lipids at the molecular level (one-way ANOVA), several molecular lipids
were elevated in the G+/LVH+ group (Table 4). Out of the 238 lipids, 28 were different
between the groups. Several TGs were increased in the G+/LVH+ group compared to the con-
trol group, and some also to the G+/LVH- group. These TGs all had long-chain, even-num-
bered (54–58 carbons) fatty acids and were mostly polyunsaturated (4–7 double bonds). The
only TG which was decreased in the G+/LVH+ group as compared to both the control group
and G+/LVH- group was a triglyceride with an odd number of acyl carbons; TG(53:7)
(p = 0.024 and p = 0.026, respectively). Most of the TGs were marginally increased in the G
+/LVH- group compared to the control group, although none of the differences was statisti-
cally significant. The two ether phospholipids PE(38:6e) and PE(38:7e) were increased in the G
+/LVH+ group compared to the control group.
When analyzing individual polar metabolites, six were different between the groups
(Table 4). All three BCAAs were increased in the G+/LVH+ group. Valine was 1.12-fold higher
compared to the control group and 1.05-fold compared to the mutation carriers in the G
+/LVH- group (p = 0.021). Leucine and its metabolic product, 4-methyl-2-oxovaleric acid
(ketoleucine), had even higher concentrations in the G+/LVH+ group compared to the other
groups (p = 0.05 and p = 0.007, respectively). Leucine was increased 1.18-fold compared to the
control group (p = 0.041), and 4-methyl-2-oxovaleric acid was increased 1.24-fold (p = 0.013)
and 1.2-fold (p = 0.041) compared to the control group and mutation carriers without LVH,
respectively. Because of the difference in age and gender between the groups, we also per-
formed an ANCOVA adjusted for these two variables. Valine and leucine were then only mar-
ginally different (p = 0.060 and p = 0.059), while 4-methyl-2-oxovaleric acid was not significant
(S1 Table). Isoleucine was also increased in the G+/LVH+ group, by 1.19-fold compared to the
control group and 1.04-fold compared to mutation carriers without LVH, although the differ-
ences were not statistically significant.
Selected lipids and polar metabolites are shown in Fig 1b.
Correlation analysis of metabolomic variables to echocardiographic
measurements
Spearman correlation coefficients for the relationship between the metabolites and the echo-
cardiographic parameters were obtained for the pooled G+/LVH- and G+/LVH+ groups (Fig
2). In subjects with theMYBPC3-Q1061X mutation, 4-methyl-2-oxovaleric acid, alpha-keto-
glutaric acid, benzenepropanoic acid and glutamic acid were positively correlated with several
of the echocardiographic variables, such as LVEDD, MWT, LV mass and LAD. The lysopho-
spholipids, phospholipids and triglycerides were positively correlated with MWT and LV mass.
Several of the lipids were negatively correlated to TDI septal Sm, TDI lateral Sm, TDI septal
Em and TDI lateral Em, with the PE plasmalogens being significantly correlated. The odd-
numbered triglyceride TG(53:7) showed an opposite correlation pattern as compared to the
other TGs.
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Discussion
Principal findings
We have shown that the patients with HCM attributable to the Q1061X mutation ofMYBPC3
display elevated levels of several triglycerides and amino acids including BCAAs, as well as
some phospholipids, compared to control subjects without LVH. Although we did not detect
Table 4. Meanmetabolite-levels for significant molecular lipids and polar metabolites.
Metabolite-name Control (N = 20) G+/LVH- (N = 19) G+/LVH+ (N = 34) P-value
PE(38:6e) 1.46±0.86 1.17±0.68 2.18±1.19a,b 0.001
PE(38:6e) 2.93±1.07 2.39±0.64 3.56±1.32b 0.002
PE(40:8e) 0.63±0.23 0.55±0.18 0.79±0.28b 0.003
PE(38:7e) 1.17±0.57 1.04±0.67 1.69±0.83a,b 0.004
PE(36:4e) 1.14±0.34 0.93±0.24 1.33±0.50b 0.004
PE(40:8e) 1.02±0.33 0.95±0.29 1.22±0.32b 0.008
PE(38:5e) 6.65±2.04 5.45±1.93 7.62±2.86b 0.011
PE(p16:0/22:6) 2.39±0.72 2.31±0.69 2.92±0.95b 0.017
PE(40:6) 3.97±1.40 3.93±1.51 5.40±2.70b 0.019
PE(40:7e) 2.60±0.72 2.31±0.92 3.03±0.99b 0.020
PE(40:4) 10.39±3.15 10.17±2.53 12.09±3.12 0.041
PC(38:7e) 0.55±0.18 0.46±0.13 0.61±0.21b 0.023
PC(38:6e) 0.86±0.21 0.83±0.21 1.00±0.26b 0.026
PC(p16:0/20:4) 5.88±1.93 5.86±1.66 7.11±2.12 0.032
PC(30:3) 0.31±0.10 0.26±0.07 0.34±0.13b 0.037
PC(34:2e) 3.34±1.32 2.86±0.85 3.98±1.89b 0.038
TG(58:5) 0.07±0.03 0.08±0.04 0.11±0.04a,b 0.004
TG(56:4) 0.16±0.08 0.17±0.09 0.28±0.19a,b 0.005
TG(53:7) 0.12±0.03 0.12±0.04 0.09±0.03a,b 0.008
TG(56:5) 2.20±1.01 2.19±0.83 2.90±1.12a,b 0.017
TG(52:0) 0.10±0.05 0.11±0.04 0.15±0.08a 0.023
TG(54:5) 6.47±3.56 7.68±3.70 9.49±4.52a 0.031
TG(54:6) 3.74±3.24 4.65±3.34 6.15±3.77a 0.048
TG(56:6) 7.62±5.18 7.25±3.23 9.84±3.81 0.049
ChoE(20:5) 7.39±4.44 7.40±7.44 10.85±5.58 0.048
LysoPC(20:5) 0.63±0.35 0.63±0.43 0.91±0.57 0.050
SM(d18:1/16:0) 82.32±12.13 76.42±10.67 85.43±13.75b 0.050
Glutamic acid 238.16±86.99 191.38±82.56 269.83±94.89b 0.012
Threonine 259.55±91.03 264.79±113.89 200.79±82.29 0.025
2-Butenedioic acid 39.08±19.03 32.44±14.97 46.68±20.28b 0.027
4-Methyl-2-oxovaleric acid 397.08±143.47 409.86±104.14 492.86±106.10a,b 0.007
Valine 338.98±45.91 360.77±60.62 380.53±50.02a) 0.021
Leucine 260.98±61.53 296.30±80.16 307.23±60.12a 0.050
Isoleucine 115.79±33.76 132.20±41.73 137.47±29.94 0.085*
The metabolite-levels are referred to as mean±SD. Abbreviations: PE phosphatidylethanolamine, PC phosphatidylcholine, TG triglyceride. P-values are
given as one-way ANOVA. Pairwise comparisons with Tukey’s range test corrected p-values are labeled:
aP<0.05 between G+/LVH+ and control group, given as Tukey’s range test.
bP<0.05 between G+/LVH+ and G+/LVH-, given as Tukey’s range test.
*Not signiﬁcant
doi:10.1371/journal.pone.0134184.t004
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Fig 2. Correlation heatmap and scatterplots. (a) Heatmap of Spearman product-moment correlation coefficients between metabolites and
echocardiographic parameters for pooled G+/LVH- and G+/LVH+ groups. The colors represent the correlation, with red being more positive and blue more
negative. Significance is given as *(p<0.05), **(p<0.01) and ***(p<0.001). (b) Scatterplots showing the relationship between lysoPE(18:2) and MWT (left),
and PE(40:8e) and MWT (right).
doi:10.1371/journal.pone.0134184.g002
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any significant metabolite-differences between mutation carriers without hypertrophy and the
control group, there is a trend of several of the metabolites in the non-hypertrophic mutation
carrier group in the same direction as the metabolites in the hypertrophic group. In the pooled
group analysis including all subjects with theMYBPC3-Q1061X mutation, several metabolites,
including several TGs, ether PEs and lysophospholipids were significantly correlated with indi-
ces of LV remodeling such as hypertrophy, LV mass, and systolic and diastolic dysfunction,
indicating a shift in the metabolic profile with manifest hypertrophic cardiomyopathy.
In the context of current literature
To our knowledge, no metabolomics studies of HCM in humans have so far been reported. In
earlier metabolomics studies using a similar design on dilated cardiomyopathy (DCM), poten-
tial biomarkers such as steroid metabolites, glutamine, threonine and histidine were found to
be diminished and TCA cycle intermediates and lipid β-oxidation products were found to be
increased in DCM patients compared to control individuals [29]. We have previously reported
that odd-chain triglycerides are diminished in patients with DCM attributable to the mutations
in the lamin A/C gene (LMNA) [30]. In hamster models with a pathophysiology similar to
human DCM, several metabolites involved in glycolysis, pentose phosphate pathway and TCA
cycle, together with triglycerides, were decreased as compared to the control animals [18].
These studies suggest altered energy production and tissue remodeling in DCM. Comparing
the metabolomic changes in DCM to the results of this study on HCM, both exhibit a decrease
in glutamate and increase in threonine levels, but in contrast the levels of triglycerides are
decreased in DCM and increased in HCM.
Possible mechanisms
In our study, levels of several TGs with even-numbered chains were increased in hypertrophic
mutation carriers. The levels of these TGs correlated with several echocardiographic variables
such as increased wall thickness and reduced systolic and diastolic function. Substrates for
myocardial energy production in humans are variable throughout life. While the healthy adult
heart primarily oxidize long-chain fatty acids as energy supply [31], the hypertrophic and fail-
ing heart shifts towards glucose and lactate metabolism, which is also seen in conditions such
as ischemia, hypothyroidism, hypoxia, diabetes and athrophy [32]. This transition from oxida-
tive fatty acid metabolism to glucose metabolism in cardiac hypertrophy is thought to be asso-
ciated with the pathological remodeling of the heart [33]. A Finnish study of patients with
HCM attributable to the Asp175Asn mutation in the α-tropomyosin gene revealed increased
myocardial oxidative metabolism and free fatty acid metabolism in HCM patients with mild
LVH, which decreased with advanced LV hypertrophy [34]. The increased levels of circulating
TGs in HCM patients in this study might represent a shift in myocardial metabolism
substrates.
Phospholipids are major components in heart tissue, and patients with HCM exhibited ele-
vated levels of several ether phospholipids compared to mutation carriers without LVH. Earlier
animal studies on hamsters with pathophysiology similar to human DCM [18] and rats with
aortic constriction-induced LVH from birth [35] have shown contradictory results on phos-
pholipid composition. Although these remodeling processes probably are different from that of
HCM, they indicate a dysregulation of membrane phospholipid homeostasis which may con-
tribute to the development of several cardiomyopathies [36].
In addition to increased lipid levels, HCM patients displayed increased levels of the BCAAs
valine and leucine, which are catabolized in non-hepatic tissue, such as cardiac muscle [37].
We found that leucine clusters with isoleucine, meaning they show a similar concentration-
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pattern among the subjects, while 4-methyl-2-oxovaleric acid clusters together with valine in
the larger MC1 cluster. BCAAs are converted into branched-chain α-keto-acids (BCKA) and
further into propionyl-CoA by the BCKA dehydrogenase complex (BCKD), before it is
degraded into acetyl-CoA or succinyl-CoA and enters the citric acid cycle. The BCKD complex
must be dephosphorylated by a protein phosphatase, PP2C, in order to be active [38]. Studies
show a high expression of mitochondrial PP2C (PP2Cm) in cardiac muscles in zebra-fish
embryos and adult mice, with stress being an important regulator, as demonstrated by signifi-
cantly reduced expression of both PP2C mRNA and protein in hypertrophic and failing hearts
[39]. This reduction leads to elevated plasma levels of BCAA and BCKA in PP2Cm-deficient
mice [38].
Morpholinos employed to suppress expression of PP2Cm in developing zebra-fish embryos
resulted in dose-dependent development defects, contractile dysfunction and heart failure [39].
BCAAs are also efficient activators of the mTOR (mammalian target of rapamycin) pathway,
which regulates protein synthesis. A local elevation of BCAA concentrations may lead to
chronic induction of mTOR, promoting cardiac hypertrophy by altering insulin sensitivity
[37]. The early development of HCM is characterized by reduced energy efficiency as shown
previously by diminished PCr/ATP ratio and myocardial external efficiency even in carriers of
HCMmutations without hypertrophy [40,41]. TheMYBPC3-Q1061X mutation most likely
results in haploinsufficiency leading to contractile impairment and impaired energy utilization
[42,43]. The LV septum requires most energy in contraction and Ashrafian et al. have hypothe-
sized that this chronic energy depletion leads through myocyte dysfunction, AMP-activated
protein kinase activation and increase in cytosolic Ca2+ into the characteristic asymmetric sep-
tal hypertrophy most commonly seen in HCM [44].
This is the first study to our knowledge to incorporate comprehensive metabolomics analy-
sis and modern echocardiographic data in carriers of a single HCM-causing mutation. The
metabolomic profile of increased TGs and BCAAs in HCM patients might indicate a change in
energy metabolism similar to that observed in heart failure and hypertrophy due to other
causes. The observed trend of these metabolites in the G+/LVH- group, in the same direction
as in the HCM patients, might indicate that some changes in metabolism occur already before
clinical hypertrophy, despite the lack of significance. Metabolomics might aid in finding non-
hypertrophic mutation carriers who are at risk of developing HCM.
Limitations of the study
Even though the study population was relatively small and heterogeneous, and some HCM
patients had hypertension, all participants with HCM had theMYBPC3-Q1061X mutation pri-
marily responsible for hypertrophic changes. Also, because the metabolome is sensitive to vari-
ous changes unrelated to the disease process in question, we tried to minimize these effects
with cluster analysis, use of control subjects from the same families to minimize genetic differ-
ences, and age-adjustment of comparisons. The study subjects had normal Finnish diet. Finally,
although theMYBPC3-Q1061X mutation is rare outside Finland, current literature suggest
that most of the knownMYBPC3mutations lead to similar haploinsufficiency through trun-
cated proteins, which are not detectable in the myocardium [42,43]. Therefore, the presented
metabolic changes may not just be specific to theMYBPC3-Q1061X mutation, but may repre-
sent changes common to otherMYBPC3mutations resulting in truncated proteins.
Conclusions
In conclusion, we have identified several metabolic changes that appear to be associated with
HCM attributable to theMYBPC3-Q1061X mutation. Especially the branched chain amino
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acids valine and leucine, 4-methyl-oxovaleric acid and PUFA-containing long chain TGs tend
to show an increasing trend between the three groups, with significant differences between the
G+/LVH+ and the control groups. Possible clinical implications for the findings in this study
may include the use of the elevated levels of metabolites as biomarkers of the LV remodeling
process in HCM, but more studies are needed to investigate the temporal relationship between
the levels of metabolites and echocardiographic findings in LV remodeling.
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